Theralase says X-ray drug effective in cancer models

Ms. Kristina Hachey reports THERALASE(R) DEMONSTRATES EFFECTIVENESS OF X-RAY-ACTIVATED DRUG Theralase Technologies Inc. has shared a scientific poster which demonstrates the effectiveness of X-ray-activated Rutherrin for numerous cancers in preclinical models. Theralase was unable to attend the presentation of the poster in person titled, "Rutherrin Activated by Radiation Therapy Induces Synergistic tumour Regression through Direct Destruction and Immune Activation in Multiple Preclinical Cancer Models." The abstract has been published in the International Journal of Radiation Oncology -- Biology -- Physics. Key findings: Enhanced tumour destruction: Radiation-activated Rutherrin achieved a 100-fold increase in cancer cell kill versus radiation therapy alone. Oxidative and immune mechanisms: Rutherrin increased reactive oxygen species (ROS) production and stimulated immune-related cytokine and chemokine expression, driving both immediate and immune-mediated cancer cell death. Overcoming resistance: The compound modulated drug efflux pathways, helping overcome mechanisms associated with multidrug and radiation resistance. Durable immune memory: In vivo, Rutherrin combined with radiation induced complete tumour regression in colorectal models and provided long-term protection against tumour rechallenge. Tumour selectivity and survival: In GBM models, Rutherrin demonstrated greater than 10-fold preferential tumour uptake over healthy brain tissue and, in both GBM and lung models, significantly prolonged survival compared with radiation alone. These key findings support Rutherrin as a promising addition to radiation therapy, capable of improving local tumour control, overcoming treatment resistance and stimulating systemic immunity. Mark Roufaiel, PhD, research scientist at Theralase, stated, "The preclinical research has demonstrated the utility of X-ray-activated Rutherrin as a preferred addition to radiation therapy to increase efficacy, improve local tumour control, overcome treatment resistance and stimulate systemic immunity." Arkady Mandel, MD, PhD, DSc, chief scientific officer of Theralase, added, "Next steps in our research program are to complete good laboratory practice toxicology studies in 2026, paving the way for the launch of clinical development targeting GBM, NSCLC, pancreatic, lymphoma and colorectal cancers." Roger DuMoulin-White, BSc, PEng, ProDir, president and chief executive officer of Theralase, stated: "We are proud to share our scientific research demonstrating Rutherrin's unique characteristics in the destruction of cancer. The patented compound amplifies radiation's direct cytotoxic effects, while stimulating a durable immune response, positioning it as a potential breakthrough in the management of aggressive cancers." About Theralase Technologies Inc. Theralase is a clinical-stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. We seek Safe Harbor.